Previous studies showed that TAT-Cx43266–283 exhibits higher tumor cell selectivity and less toxicity than the Src inhibitor, dasatinib.36,37 Interestingly, in the human and mouse GSCs analyzed in the present study we found that the antitumor effect of TAT-Cx43266–283 was higher than that of TMZ, the standard treatment for GBM, and erlotinib, an inhibitor of EGFR with disappointing results in GBM clinical trials.45 In fact, so far EGFR inhibitors have not resulted in positive results in clinical trials, despite selecting GBM patients with specific EGFR alterations. The gene discussed is SRC; the disease is neoplasm.